Drug Approval | May 07, 2026
This is an exciting and meaningful milestone for GRIN Therapeutics
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The precision health platform integrates genetics, biomarkers, diet, and lifestyle data to deliver personalised gut health interventions and therapy support
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
New pediatric nebulizer combines playful design and engaging features to make breathing treatments less stressful for children and parents
Subscribe To Our Newsletter & Stay Updated
